Table 1.
Angiogenic factors that were up-regulated in human bone marrow osteoclast cultures
| Angiogenic factor | RANKL + M-CSF culture expression relative to housekeeping genes* | Fold increase vs M-CSF–treated cultures† |
|---|---|---|
| MMP-9 | 47 | 7.1 |
| ANPEP (APN, CD13) | 0.48 | 4.1 |
| β3-integrin | 0.069 | 28.2 |
| MMP-2 | 0.069 | 7.1 |
| Neuropilin-2 | 0.060 | 5.7 |
| Sphingosine kinase 1 | 0.020 | 11 |
| CXCL5 (ENA-78) | 0.012 | 8.1 |
| Notch-4 | 0.0061 | 5.0 |
| COL18A1 (endostatin) | 0.0026 | 8.1 |
| Angiopoietin-2 | 0.00020 | 4.1 |
RANKL indicates receptor activator of nuclear factor-κB ligand; M-CSF, macrophage colony-stimulating factor; and MMP, matrix metalloproteinase.
Expression levels of genes involved in angiogenesis were determined with the SA Biosciences Human Angiogenesis Q-PCR array in bone marrow cultures treated with RANKL and M-CSF or M-CSF alone. Expression levels were normalized to the average Ct value of five housekeeping genes (B2M, HPRT1, RPL13A, GAPD, and ACTB) as recommended by the manufacturer. Expression levels in cultures treated with RANKL and M-CSF are reported in the middle column.
The relative, normalized expression levels of genes involved in angiogenesis were then compared between cultures treated with RANKL and M-CSF to cultures treated with M-CSF alone by dividing the expression levels in the RANKL + M-CSF culture by the expression levels in the M-CSF only culture. Results are reported in the right column as fold increase compared with cultures treated with M-CSF alone. Only genes whose expression was increased at least 4-fold are reported.